Exelixis’s Cabometyx Two-For-Two In A Week As Neuroendocrine Tumor Study Hits Endpoint

 
• By Alaric DeArment
Exelixis said the Phase III CABINET trial in neuroendocrine tumors met its primary endpoint • Source: Shutterstock

More from Clinical Trials

More from R&D